Our top pick for
Building a portfolio
Entasis Therapeutics Holdings Inc is a biotechnology business based in the US. Entasis Therapeutics shares (ETTX) are listed on the NASDAQ and all prices are listed in US Dollars. Entasis Therapeutics employs 47 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$1.58 - $4.25|
|50-day moving average||$2.42|
|200-day moving average||$2.37|
|Wall St. target price||$6.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.33|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Entasis Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Entasis Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Entasis Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Entasis Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||$7 million|
|Return on assets TTM||-60.21%|
|Return on equity TTM||-106.93%|
|Market capitalisation||$70.9 million|
TTM: trailing 12 months
There are currently 226,005 Entasis Therapeutics shares held short by investors – that's known as Entasis Therapeutics's "short interest". This figure is 17.8% down from 274,780 last month.
There are a few different ways that this level of interest in shorting Entasis Therapeutics shares can be evaluated.
Entasis Therapeutics's "short interest ratio" (SIR) is the quantity of Entasis Therapeutics shares currently shorted divided by the average quantity of Entasis Therapeutics shares traded daily (recently around 265888.23529412). Entasis Therapeutics's SIR currently stands at 0.85. In other words for every 100,000 Entasis Therapeutics shares traded daily on the market, roughly 850 shares are currently held short.
However Entasis Therapeutics's short interest can also be evaluated against the total number of Entasis Therapeutics shares, or, against the total number of tradable Entasis Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Entasis Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Entasis Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0076% of the tradable shares (for every 100,000 tradable Entasis Therapeutics shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Entasis Therapeutics.
Find out more about how you can short Entasis Therapeutics stock.
We're not expecting Entasis Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Entasis Therapeutics's shares have ranged in value from as little as $1.58 up to $4.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entasis Therapeutics's is 1.9199. This would suggest that Entasis Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co. , Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.